<i>KIT</i> ‐mutated pediatric core‐binding factor systemic mastocytosis‐acute myeloid leukemia treated with avapritinib and decitabine
Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Miriam B. Garcia(The University of Texas MD Anderson Cancer Center), Maro Ohanian(The University of Texas MD Anderson Cancer Center), Michael Roth(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Jeremy Connors(The University of Texas MD Anderson Cancer Center), David McCall(The University of Texas MD Anderson Cancer Center), Dristhi Ragoonanan(The University of Texas MD Anderson Cancer Center), Amber Gibson(The University of Texas MD Anderson Cancer Center), Shaikha Alqahtani(Duke University), César Núnêz(The University of Texas MD Anderson Cancer Center), C. Cameron Yin(Chinese Academy of Agricultural Sciences)
Cited by 5
Related Papers
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
|Nature Medicine|2023|372
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
|Blood|2016|346
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
|Blood|2012|340
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
|Journal of Clinical Oncology|2021|333